Document Classification

Section Type: RESULTS

Text: By contrast, there were no significant differences by treatment group for patients with EGFR Leu858Arg-positive tumours in either trial : in LUX-Lung 3, median overall survival was 27. 6 months (19. 8-41. 7) in the afatinib group versus 40. 3 months (24. 3-not estimable) in the chemotherapy group (HR 1. 30, 95 % CI 0. 80-2. 11, p = 0. 29) ; in LUX-Lung 6, it was 19. 6 months (95 % CI 17. 0-22. 1) versus 24. 3 months (19. 0-27. 0), respectively (HR 1. 22, 95 % CI 0. 81-1. 83, p = 0. 34).